

8th

International Conference on

**CANCER
RESEARCH &
DRUG
DEVELOPMENT**



November 13-15, 2023
Boston, MA



Boston Marriott Newton Hotel
2345 Commonwealth Avenue
Newton, MA 02466, United States

Silver Sponsor



kiburmedical

13-Nov-23

Day **01**

Meeting Room: Salons ABCD

Join Zoom Meeting:

<https://zoom.us/j/97442431745?pwd=cUtmL3UxdTFBWWNsSkV6dXBjYmM2NTxQT09>

Meeting ID: 974 4243 1745

Passcode: 980967

8:00-9:00 Registrations

@ Foyer

9:00-9:10 Introduction and Welcome Message

Khosrow Kashfi, The City College of New York, NY

Plenary Session 1

9:10-10:30


Chair: Khosrow Kashfi, The City College of New York, NY



Raghu Kalluri

The University of Texas MD Anderson
Cancer Center, TX

**Lessons Learned by Unraveling the Basic Biology and
Clinical Translation of Extracellular Vesicles and Exosomes**



Douglas R Green

St. Jude Children's Research Hospital, TN

**Near Death Experiences in Cancer Cells and Residual
Disease**

10:30-10:45 Break

@ Foyer

Plenary Session 2

10:45 -12:45

Chair: Rachel Karchin, Johns Hopkins University, MD



Ali Shilatifard

Northwestern University Feinberg School
of Medicine, IL


**Epigenetic Moonlighting:
Bromodomain-Independent Function
of BRD4 in Transcriptional Regulation**



A Thomas Look

Dana-Farber Cancer Institute, Harvard
Medical School, MA

**Differentiation Therapy of
Neuroblastoma with Isotretinoin Acts
by Remodeling Nuclear Structure**



Robert Weinberg

Founding Member, Whitehead Institute for
Biomedical Research, Director, MIT Ludwig
Center for Molecular Oncology, Cambridge

**Mechanisms of Malignant
Progression**

12:45-13:30 Group Photo Session & Lunch

@ Foyer

Plenary Session 3

13:30 -15:30

Chair: **Lee M. Graves**, The University of North Carolina, NC



Andy Loboda

Director at Merck, Boston
Molecular Biomarkers of Response to
Keytruda



Dae Yoon Chi

CEO, FutureChem Co Ltd, Korea
Use of Radiopharmaceutical Imaging
Drugs for the Development of
Therapeutic Drugs: Theranostic
Lutetium-177-Labeled Lutetadipep with
an Albumin Binder for Prostate Cancer



Li Peng

Chief Scientific Officer at Palleon
Pharmaceuticals, Boston
Unlocking the Therapeutic Potential
of Glyco-Immunology to Treat Cancer
by Targeting Sialoglycans

15:30-15:40 Coffee Break

@ Foyer

Keynotes

15:40-17:40

Chair: **Mats Ljungman**, University of Michigan Medical School, MI



X. Shirley Liu

Co-founder & CEO, GV20 Therapeutics,
MA
Integrated Genomics and
Computation for Cancer Target and
Drug Discovery



Ji-Xin Cheng

Boston University Photonics Center, MA
Bond-selective Imaging of Altered
Cancer Metabolism



Benjamin Haibe-Kains

Princess Margaret Cancer Centre,
University Health Network, Canada
Meta-analysis of Preclinical
Pharmacogenomic Studies to
Discover Robust and Translatable
Biomarkers of Drug Response



Colin Brenan

CEO, Kibur Medical Inc, MA
A Rational Approach to
Identification of Highly Synergistic
Combinations between Targeted
Agents, Chemotherapies and
Immunotherapies in Breast Cancer



Xi Chen, Baylor College of Medicine, TX
Stressing Out Therapy-Resistant Cancers

18:00-19:00 Networking and Drinks

@ Foyer

Posters

@ Lexington

- P-01** **Mohammed Quamruzzaman**, University College London, UK
Novel STAT3 Small-Molecule Inhibitor Development as a Potential Anticancer Drug Targeting STAT3 Signalling Pathway
- P-02** **Mei Cai**, California University of Science and Medicine, CA
Chmp1A Regulates Pancreatic Cancer Growth Partly Through Post-Translational Modification by SUMO and Ubiquitin
- P-03** **Yash Singh**, University of Central Florida College of Medicine, Orlando, FL, USA
A Retrospective Evaluation of Incidence and Timing of Radiation Necrosis for Patients with Brain Metastases from Lung Cancer Treated with Stereotactic Radiosurgery
- P-04** **Morgan Eikanger**, University of South Dakota, SD
Veratridine, an Anti-mTORC2 Mechanism for both Primary and Metastatic Colon Cancer
- P-05** **Crisalde Ramirez-Celis**, National Autonomous University of Mexico (UNAM), Mexico
Effect of Zidovudine (Azt), Adenosine (Ado) and their Coadministration in Hepatic Cells
- P-06** **Seiji Okada**, Kumamoto University, Japan
Elotuzumab, a Humanized Anti-SLAMF7 Monoclonal Antibody, enhances Natural Killer Cell and V γ 9V δ 2 T Cell-mediated Killing of Primary Effusion Lymphoma Cells
- P-07** **Kayla Martinez**, Ross University School of Medicine, USA
Low-Grade Endometrial Stromal Sarcoma with Parametrium Invasion -A Case Report
- P-08** **Jutatip Panaampon**, Kumamoto University, Japan
MICA/B Expression on ATL cells is Crucial for NK Cytotoxicity
- P-09** **Sanam Sane**, University of South Dakota, SD
Mechanistic Studies of UBXN2A-RICTOR-mTORC2 Axis in Human Colorectal Cancer
- P-10** **Amin Benyounes**, Inova Schar Cancer Institute, VA
Local Consolidation Radiation Therapy in Patients with EGFR Mutated non-small cell lung Cancer (NSCLC) receiving Frontline Osimertinib, a Real-World Experience
- P-11** **Shiyi Qin**, Medical School of Nantong University, China
Plasma circXPO1: a Novel Diagnostic Biomarker Promotes Gastric Cancer Progression through the circXPO1-miRNA-mRNA Axis
- P-12** **Venugopaloreddy Mekala**, Baylor College of Medicine, TX
Effect of Epigenetic Regulators on Clinical Outcomes in Bladder Cancer
- P-13** **Amy M Rojiani**, Penn State Cancer Institute, PA
TIMP-1 and Extracellular Matrix Hyaluronic Acid Contribute to Tumor Growth in NSCLC
- P-14** **Irshad Arshad**, New Mexico Highlands University, United States
Title to be updated

Join Zoom Meeting:<https://zoom.us/j/97442431745?pwd=cUtmL3UxdTFBWWNsSkV6dXBjYmM25xQT09>

Meeting ID: 974 4243 1745

Passcode: 980967

Cancer Immunotherapies: Monotherapy and Combinations**Chairs:** **Marion R. Curtis**, Mayo Clinic, AZ**Lucas Ferrari de Andrade**, Icahn School of Medicine at Mount Sinai, NY**Keynote****8:00-8:30****8:00-8:30****Michael Yaffe**

Massachusetts Institute of Technology, MA

Using Protein Kinase Signaling and DNA-damaging Chemotherapy to Enhance Cancer Immunotherapy Treatment**8:30-8:50****Duxin Sun**, The University of Michigan, MI**Why 95% of Cancer Drug Development Fails and How to Improve it?****8:50-9:10****Rachel Karchin**, Johns Hopkins University, MD**Predicting Immunogenic Neopeptides in Cancers****9:10-9:30****Lee M. Graves**, The University of North Carolina, NC**Optimized Small Molecule Activators of the Mitochondrial Protease ClpP as Anti-Cancer Agents****9:30-9:50****Yi Zheng**, Cincinnati Children's Hospital Medical Center, OH**Rational Targeting a Rho GTPase to benefit Cancer Immunotherapy****9:50-10:10****Jing Hong Wang**, University of Pittsburgh School of Medicine, PA**Divergent Outcomes of Anti-PD-L1 Treatment Coupled with Host-Intrinsic Differences in TCR Repertoire in Responding versus Non-Responding Tumors****10:10-10:30****Mar Valés-Gómez**, Spanish National Research Council, Spain**Long-term Activation of Anti-Tumour Innate Lymphocytes with BCG-Priming****10:30-10:40 Coffee Break****@ Foyer**



10:40-11:00

Jenny Zilberberg, Head of Research, Imvax Inc., PA
Goldspire™: A Biologic-Device Combination Platform to Elicit Immunogenic Cell Death-Associated Anti-Tumor Responses in Solid Malignancies



11:00-11:20

Jessica E. Thaxton, University of North Carolina at Chapel Hill, NC
Endoplasmic Reticulum Distress Underlies CD8 TIL Dysfunction



11:20-11:40

Fahri Saatcioglu, University of Oslo, Norway
Targeting the Unfolded Protein Response to Alleviate the Immunosuppressive Tumor Microenvironment in Prostate Cancer



11:40-12:00

Julie Oh, A2 Biotherapeutics, CA
The Tmod Cellular Logic Gate as a Solution for Tumor-Selective Immunotherapy



12:00-12:20

Christopher A Pennell, Masonic Cancer Center, MN
Mechanisms of CAR T-cell Induced Neurotoxicity



12:20-12:40

Namhee Lee, SillaJen, Inc., South Korea
Generation of Novel Oncolytic Vaccinia Virus with Improved Intravenous Efficacy

Group Photo Session

12:40-13:30 Lunch Break


@ Foyer

Chairs: Jing Hong Wang, University of Pittsburgh School of Medicine, PA
Christopher A Pennell, Masonic Cancer Center, MN



13:30-13:50

Marion R. Curtis, Mayo Clinic, AZ
Inhibition of DNA Damage Repair Through the Targeting of Protein Phosphatase 4 to Enhance Anti-Tumor Immunity



13:50-14:10

Jason T. George, Texas A&M University, TX
Stochastic Modeling for Quantifying 'Smart' Cancer Immune Evasion Strategies



14:10-14:30

Alice Cheung, Duke-NUS Medical School, Singapore
Cord Blood Derived $\gamma\delta$ T cells for Cancer Immunotherapy



14:30-14:50

Yinan Gong, University of Pittsburgh, PA
Cancer Plasma Membrane Dynamics and Signaling in Cancer Immunology



14:50-15:10

Liya Ding, Roswell Park Comprehensive Cancer Center, NY
Remodeling Immunosuppressive Tumor Microenvironment with STING agonist for Cancer Treatment



15:10-15:30

Di Zhao, MD Anderson Cancer Center, TX

Novel strategies Targeting Immune Checkpoint B7-H3 in Advanced Prostate Cancer

15:30-15:40 Coffee Break

@ Foyer



15:40-16:00

Lucas Ferrari de Andrade, Icahn School of Medicine at Mount Sinai, New York, NY

Promoting Innate Immunity against Diverse Cancer Types through a Novel Antibodybased Approach



16:00-16:20

Degen Zhuo, BioTailor Inc, FL

Hereditary Fusion Genes Commence the Biomedical Revolution: Are You Ready?



16:20-16:40

Hannah Knochelmann, Medical University of South Carolina, SC

B cells License Long-Lived Antitumor Immunity for Adoptively Transferred Th17 Cells



16:40-17:00

Xinhui Wang, Massachusetts General Hospital, Harvard Medical School, MA

Innovative Strategies: Enhancing CAR T Therapy for Solid Tumors



17:00-17:20

Richard Kolesnick, Memorial Sloan Kettering Institute, NY

ABC1-Mediated Multi-Drug Resistance is a "Ceramidopathy" Treatable with a C16:0 Ceramide Nanoliposome

14-Nov-23

Day **02**

Parallel Session II @ Commonwealth 3

Join Zoom Meeting:

<https://us06web.zoom.us/j/88043465179?pwd=DN9Fpew7NuHUbMgC6ziciHn7vlyqRB.1>

Meeting ID: 880 4346 5179

Passcode: 988055

Cancer Biology

Chair: Stefanie Galban, University of Michigan, MI
Marcin Iwanicki, Stevens Institute of Technology, NJ

Keynotes

8:00-09:00



Alan D. D'Andrea

Dana-Farber Cancer Institute, MA

Novel Therapies for BRCA1/2 deficient Cancers



Keith T. Wilson

Vanderbilt University Medical Center, TN

Dicarbonyl Electrophile Scavengers as a New Strategy for Prevention and Treatment of Gastric and Colorectal Cancer



9:00-9:20

Edward V. Prochownik, Children's Hospital of Pittsburgh, PA
Premature Aging and Reduced Cancer Incidence Associated with Near-Total Body-Wide Knockout of Myc



9:20-9:40

Jing Huang, NCI, National Institutes of Health, MD
The Role of RUNX2 in Regulating Innate Immunity in Osteosarcoma Cells



9:40-10:00

Lixing Yang, The University of Chicago, IL
Use Large-Scale Genomics Data to Understand Genome Instability and Guide Treatment

10:00-10:10 Coffee Break

@ Foyer



10:10-10:30

Subhamoy Dasgupta, Roswell Park Comprehensive Cancer Center, NY
Nuclear Metabolic Pathway Regulating Epigenetic Rewiring in Tumors



10:30-10:50

Nagi G Ayad, Georgetown University, DC
Chemical Biology Approaches for Treating Brain Cancers



10:50-11:10

Wolf-Karsten Hofmann, University Hospital Mannheim, Heidelberg University, Germany
Inhibition of Lysyl Oxidases Synergizes with 5-azacytidine to Restore Erythropoiesis in Myeloid Malignancies



11:10-11:30

Carla Van Den Berg, The University of Texas at Austin, TX
Potential Drug Target TFEB Mediates Metabolic Stress and Cancer Stem Cells in Triple Negative Breast Cancer



11:30-11:50

Qin Feng, University of Houston, TX
Tudor Monarch of Cell Proliferation in Prostate Cancer Development



11:50-12:10

Young-Mee Kim, University of Illinois at Chicago, IL
The Role of Skeletal Muscle Endothelial Dysfunction in Cancer Cachexia



12:10-12:30

Zhou Wang, University of Pittsburgh, PA
Targeting Androgen Receptor in the Nucleus of Castration-Resistant Prostate Cancer

Group Photo Session

12:30-13:10 Lunch Break

@ Foyer

Chair: **Jing Huang**, NCI, National Institutes of Health, MD
Lixing Yang, The University of Chicago, IL




13:10-13:30

Marcin Iwanicki, Stevens Institute of Technology, NJ
Taurine Activates Tumor Suppression Mechanisms in Ovarian Cancer



13:30-13:50

Stefanie Galban, University of Michigan, MI
The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer



13:50-14:10

Yan Peng, University of Texas Southwestern Medical Center, TX
Updates in Breast Cancer Tumor Biomarkers in 2023



14:10-14:30 (Virtual Talk)

Lucia Borriello, Lewis Katz School of Medicine and Fox Chase Cancer Center, PA
How Does The Primary Tumor Imprint a Dormancy Signature in Disseminated Tumor Cells?



14:30-14:50

Soona Shin, Cincinnati Children's Hospital Medical Center, OH
Role of Beta-Catenin Signaling in Fibrolamellar Hepatocellular Carcinoma



14:50-15:10

Wenliang Li, Texas Therapeutics Institute, TX
Novel Kinase Regulators and Drug Targets in Cancer Progression and Metastasis

**15:20-15:40****Hualong Yan**, National Institutes of Health, MD**Targeting the Interacting Partners of ZMIZ1: A Novel Therapeutic Approach for Treating Osteosarcoma****15:40-16:00****Payam A Gammage**, CRUK Beatson Institute, UK**Tumour Mitochondrial DNA Mutations Drive Aerobic Glycolysis to Enhance CheckPoint Blockade****16:00-16:20****Nils Cordes**, Dresden University of Technology, Germany**Pan-FGFR Inhibition Induces Resistance Characteristics of Partial EMT in HNSCC Cell Models Associating with Clinical Outcome****16:20-16:40****Alena Malyukova**, Karolinska Institute, Sweden**Targeting Cell Fate to Block Non-Genetic Cancer Evolution in Acute Lymphoblastic Leukemia****16:40-17:00****Gamze Ayaz**, National Institutes of Health, MD**A Proteomics Approach Identifies Novel Interaction Partners of Mutant p53 in Breast Cancer****17:00-17:20****Kunihiko Hinohara**, Nagoya University, Japan**Decoding Evolutionary Trajectories of Cancer Drug Resistance****17:20-17:40****Yi Zhang**, George Washington University School of Medicine and Health Sciences, Washington, DC**And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance****17:40-18:00****Enrico Moiso**, MIT Koch Institute, MA**Developmental Deconvolution for Classification of Cancer Origin: Leveraging Genomic Atlases to Assist Cancer Diagnosis**

Join Zoom Meeting:

<https://us06web.zoom.us/j/83352149959?pwd=PNGn70Zy2YGdpyLZsXD1Pss2GBAbKk.1>

Meeting ID: 833 5214 9959

Passcode: 789328

Cancer Metastasis

Chair: **William H. Gmeiner**, Wake Forest University, NC



8:00-8:20

William H. Gmeiner, Wake Forest University, NC

Overcoming Drug Resistance in Colorectal Cancer with Polymeric Fluoropyrimidines – New Mechanistic Insights



8:20-8:40

Stephen Wong, Houston Methodist, Weill Cornell Medical College, TX

Overabundance of Phosphatidylethanolamine Flux in Obesity Escalates Cancer and Alzheimer's Disease



8:40-9:00

David Entenberg, Albert Einstein College of Medicine, NY

Shining Light on Disseminated Tumor Cell Stemness, Survival, and Dormancy



9:00-9:20

Myron Ignatius, UT Health Sciences Center, Texas

A RAS/MEK/SNAI2 Pathway Drives Resistance to Radiation in RAS Mutant Rhabdomyosarcoma Tumors



9:20-9:40

Safiah Olabi, Helmholtz Zentrum MÜNchen, Germany

Micrometastasis Imaging and Profiling in the Whole Mouse Body: Unveiling Molecular Insights



9:40-10:00

Shaheen Sikandar, University of California @ Santa Cruz, CA

Using Principles of Stem Cells to Understand Breast Cancer Metastasis



10:00-10:20

Maja H. Oktay, Montefiore Medical Center, NY

Translational and Clinical Advances Stemming from Intravital Imaging of Breast Cancer

10:20-10:30 Break

@ Foyer

Cancer Targeted Therapy

Chairs: **Khosrow Kashfi**, The City College of New York, NY

Eran Andrechek, Michigan State University, MI



10:30-10:50

Khosrow Kashfi, The City College of New York, NY

NOSH-Aspirin Protects Against Parkinson's Disease



10:50-11:10

Lih-Wen Deng, National University of Singapore, Singapore
Target Cysteine Metabolism in Ovarian Cancer Therapy



11:10-11:30

Sihan Wu, University of Texas Southwestern Medical Center, TX
Extrachromosomal DNA in Cancer - From Cancer Evolution to Therapy Resistance



11:30-11:50

Eran Andrechek, Michigan State University, MI
Integrated Genomic Analysis of Breast Cancer Models Reveals Conserved Events Impacting Outcome



11:50-12:10

Khosrow Rezvani, University of South Dakota, SD
"SMART" Nanoparticle Delivery of Veratridine Overcomes Clinical Challenges in Metastatic Colorectal Cancer

Group Photo Session

12:10-13:00 LUNCH

@ Foyer



13:00-13:20

Xiaoling Li, National Institute of Environmental Health Sciences, NC
Dietary Methionine Restriction in Cancer Therapy



13:20-13:40

Zohar Sachs, University of Minnesota, MN
Therapeutic Targeting Strategies for TP53 Mutant AML



13:40-14:00

Qingrun Zhang, University of Calgary, Canada
Stabilized COre Gene and Pathway Election Uncovers Pan-Cancer Shared Pathways and a Cancer Specific Driver



14:00-14:20

Sergey Karakashev, Temple University, PA
Targeting CARM1-Expressing Epithelial Ovarian Cancer



14:20-14:40

Young-im Kim, National Institutes of Health, MD
SOX9 is a Key Component of RUNX2-regulated Transcriptional Circuitry in Osteosarcoma



14:40-15:00

Allen C. Gao, University of California, CA
Novel Dual Targeting Androgen Receptor and AKR1C3 Signaling for Advanced Prostate Cancer



15:00-15:20

Wenge Zhu, The George Washington University School of Medicine and Health Science, DC
Targeting SENP1 to Overcome Platinum Drug Resistance in Ovarian Cancer

15:20-15:30 Coffee Break

@ Foyer

Novel Targeted Therapies

Chairs: **Lixin Rui**, University of Wisconsin-Madison, WI
Michael Goldstein, Johns Hopkins School of Medicine, MD



15:30-15:50

Andres Blanco, University of Pennsylvania School of Veterinary Medicine, PA
Identification and Interrogation of MOZ Complex Subunits Driving Differentiation Arrest in AML



15:50-16:10

Michael Goldstein, Johns Hopkins School of Medicine, MD
Using Epigenetics to Predict and Improve Treatment Response in Cancer



16:10-16:30

Satyamaheshwar Peddibhotla, University of Florida, FL
Development of CXCR6 Antagonists to Target Resistance in Hepatocellular Carcinoma



16:30-16:50

Lixin Rui, University of Wisconsin-Madison, WI
Targeting Oxidative Phosphorylation to Overcome Ibrutinib Resistance in B cell Lymphoma




16:50-17:10

Ozgur Sahin, Medical University of South Carolina, SC
Overcoming Drug Resistance in Breast Cancer



17:10-17:30

Mats Ljungman, University of Michigan Medical School, MI
KLIPP: Precision Targeting of Cancer with CRISPR



17:30-17:50

Jinfeng Zhang, Florida State University, FL
Constructing a Large-scale Knowledge Graph and Its Applications in Drug Discovery



17:50-18:10 (Virtual Talk)

Giorgia Pastorin, National University of Singapore, Singapore
Dual Action & Dual Targeting of Platinum-Based Chemotherapies

15-Nov-23

Day **03**

Meeting Room @ Commonwealth 2, 3 and 4

Join Zoom Meeting:

<https://zoom.us/j/97442431745?pwd=cUtmL3UxdTFBWWNsSkV6dXBjYmM2NTUxQT09>

Meeting ID: 974 4243 1745

Passcode: 980967

Cellular Therapies for Cancer & Tumor Microenvironment

Chair: **Kaifu Chen**, Harvard University, MA
Michelle Mendoza, University of Utah, UT

Keynotes

8:00-09:00




Kaifu Chen
Harvard University, MA

RNA m6A Landscape Reveals Strong
Vulnerability of Cancer Cells to RNA Stability
Manipulation



Constantine S Mitsiades
Harvard University, MA

Functional Genomics Studies to Identify
Therapeutic Vulnerabilities with Preferential
roles in Individual Tumor Type(s): Implications for
Lineage-Specific Therapies



9:00-9:20

Medhi Wangpaichitr, University of Miami, FL
Role of IDO/TDO Dual Inhibitor (AT-0174) in Platinum-Resistant NSCLC



9:20-9:40

Anthony Faber, VCU Philips Institute, VA
Further Targeting the Ferroptotic Vulnerability in MYCN-Amplified Neuroblastoma



9:40-10:00

Michelle Mendoza, University of Utah, UT
Strain Signaling and Extracellular Matrix in Early Lung Cancer



10:00-10:20

Dawn S Nin, National University of Singapore, Singapore
A Multi-Analyte-based Stratification Methodology for Predicted Response to
Radiotherapy in Patients with Stage IIA-IIIC Locally Advanced Cervical Cancer



10:20-10:40

Zhe Ji, Northwestern University, IL
Noncanonical Translation in Cancers

10:40-10:50 Coffee Break

@ Foyer



10:50-11:10

Romi Gupta, The University of Alabama at Birmingham, AL
UBE2T Promotes Breast Cancer Tumor Growth by Suppressing DNA Replication Stress



11:10-11:30

Dimitris Anastassiou, Columbia University, NY
The APOD+DCN+LUM+Cell Population and its Fibroblastic Differentiation in the Chemo-Resistant Tumor Microenvironment



11:30-11:50

Peiwen Chen, Northwestern University, IL
Targeting Immunosuppressive Tumor Microenvironment in Glioblastoma



11:50-12:10

Martin K. Thomsen, Aarhus University, Denmark
Unraveling the Genetics of Prostate Cancer in vivo using CRISPR Modeling



12:10-12:30

Guangwen Gary Ren, The Jackson Laboratory, Bar Harbor, ME
Stromal Cell-Immune Cell Interactions in the Lung Pre-Metastatic Niche



12:30-12:50

Amanda C. Poholek, University of Pittsburgh School of Medicine, PA
Tumor Microenvironment Signals Shape the Epigenome of Exhausted T Cells



12:50-13:10

Tracy Murray Stewart, Johns Hopkins School of Medicine, MD
HDAC10 Deacetylates Extracellular Polyamine Metabolites to Support Tumor Growth



13:10-13:30

Eugen Dhimolea, Albert Einstein College of Medicine, NY
Exploring the Therapeutic Vulnerabilities of Treatment-Persistent Cancer Cells



13:30-13:50

Mumtaz V Rojiani, Penn State Cancer Institute, PA
Role of TIMP-1 in chemoresistance in NSCLC



13:50-14:00

K. Michael Conrad, Tulane University, New Orleans, LA
Confirmation of Proposed Xenohormetic Protection by Phytochemicals in Human Microphysiological Models of Tissue Vasculogenesis and Cancer-Induced Angiogenesis



14:00-14:20 (Virtual Talk)

David Potter, University of Minnesota, MN
Modulating the Immune Microenvironment of ER+HER2- Breast Cancer

14:20 Lunch and Departures

Contact:

Kinnera Kalagara

Conference Manager-Cancer R&D 2023



UNITED | Scientific
Group

A non-profit organization

USG United Scientific Group (A non-profit organization)

8105, Suite 112, Rasor Blvd, PLANO, TX 75024

Tel: +1 469-854-2280/81

Email: kkalagara@uniscigroup.net

Web: <https://cancerresearchconference.org/>